A trial to test if the combination of encorafenib, binimetinib and cetuximab is safe and effective in participants with BRAFV600E-mutant metastatic colorectal cancer.
A trial to test if the combination of encorafenib, binimetinib and cetuximab is safe and effective in participants with BRAFV600E-mutant metastatic colorectal cancer.
Phase 2, open-label, single arm, multicenter study of Encorafenib, Binimetinib plus Cetuximab in subjects with previously untreated BRAFV600E -mutant metastatic colorectal cancer
Brief summary
The purpose of the trial is to find out whether combining three different medicines, encorafenib, binimetinib and cetuximab is safe and effective in people with metastatic colorectal cancer carrying a specific mutation in the BRAF gene (BRAFV600E) and who had not previously received any therapy for their disease.
Encorafenib, binimetinib and cetuximab may turn off the effect of this BRAF mutation, each acting in a different way.
Find out where the clinical trial is / was conducted
Contact Us
Need more information, click on the button to have access to the contact form.
Access to Lay Protocol Synopsis
Un résumé du protocole rédigé en termes simples et décrivant les objectifs de l’étude vous est proposé.